Adverse events caused by drug interactions involving glucuronoconjugates of zidovudine, valproic acid and lamotrigine, and analysis of how such potential events are discussed in package inserts of Japan, UK and USA

Journal of Clinical Pharmacy and Therapeutics

Volumn 32, Issue 2, 2007, Pages 177-185

  Hirata Koizumi, M ^a   Saito, M ^a   Miyake, S ^a   Hasegawa, R ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Adverse event; Drug interaction; Glucuronidation; Glucuronoconjugate; Package insert

Indexed keywords

ATOVAQUONE; CARBAPENEM DERIVATIVE; DRUG METABOLITE; ESTROGEN; ETHINYLESTRADIOL; FLUCONAZOLE; GESTAGEN; GLUCURONIC ACID; IMIPENEM; INDOMETACIN; LAMOTRIGINE; LOPINAVIR PLUS RITONAVIR; MEROPENEM; METHADONE; ORAL CONTRACEPTIVE AGENT; PANIPENEM; PROBENECID; RIFAMPICIN; RITONAVIR; TEMAZEPAM; VALPROIC ACID; ZIDOVUDINE;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BIPOLAR DISORDER; DIZZINESS; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG INFORMATION; DRUG INTERACTION; DRUG POTENTIATION; DRUG TOLERANCE; EPILEPSY; GLUCURONIDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPAN; MANIA; NAUSEA; NONHUMAN; RHEUMATOID ARTHRITIS; SEIZURE; UNITED KINGDOM; UNITED STATES; VOMITING;

AREA UNDER CURVE; COMMUNICATION; DISCLOSURE; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG LABELING; GLUCURONATES; GREAT BRITAIN; HALF-LIFE; HUMANS; JAPAN; PHARMACEUTICAL PREPARATIONS; TRIAZINES; UNITED STATES; VALPROIC ACID; ZIDOVUDINE;

EID: 33947383703     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2007.00814.x     Document Type: Article

References (70)

1. Saito M, Hirata Koizumi M, Urano T, Miyake S, Hasegawa R (2005) A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. Journal of Clinical Pharmacy and Therapeutics, 30, 21-37.
2. Saito M, Hirata Koizumi M, Miyake S, Hasegawa R (2005) Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). European Journal of Clinical Pharmacology, 61, 531-536.
3. Willkinson GR (2001) Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's the pharmacological basis of therapeutics, 10th edn. New York: McGraw-Hill, 3-29.
4. Ouzzine M, Barre L, Netter P, Magdalou J, Fournel Gigleux S (2003) The human UDP-glucuronosyltransferases: structural aspects and drug glucuronidation. Drug Metabolism Reviews, 35, 287-303.
5. Kiang TK, Ensom MH, Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacology & Therapeutics, 106, 97-132.
6. Lin JH, Wong BK (2002) Complexities of glucuronidation affecting in vitro in vivo extrapolation. Current Drug Metabolism, 3, 623-646.
7. PDR (2006). PDR Electronic Library Version 7.0.306a - 2006.1. New Jersey: Thomson PDR.
8. Lertora JJ, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE Jr, Agrawal KC. (1994) Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clinical Pharmacology and Therapeutics, 56, 272-278.
9. Antoniou T, Gough K, Yoong D, Arbess G (2004) Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. Clinical Infectious Diseases, 38, e38-40.
10. Sahai J, Gallicano K, Pakuts A, Cameron DW (1994) Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. The Journal of Infectious Diseases, 169, 1103-1107.
11. Brockmeyer NH, Tillmann I, Mertins L, Barthel B, Goos M (1997) Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. European Journal of Medical Research, 2, 377-383.
12. Kornhauser DM, Petty BG, Hendrix CW, Woods AS, Nerhood LJ, Bartlett JG, Lietman PS (1989) Probenecid and zidovudine metabolism. Lancet, 2, 473-475.
13. de Miranda P, Good SS, Yarchoan R, Thomas RV, Blum MR, Myers CE, Broder S (1989) Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clinical Pharmacology and Therapeutics, 46, 494-500.
14. McCance Katz EF, Rainey PM, Jatlow P, Friedland G (1998) Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18, 435-443.
15. Lee BL, Tauber MG, Sadler B, Goldstein D, Chambers HF (1996) Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clinical Pharmacology and Therapeutics, 59, 14-21.
16. Gallicano KD, Sahai J, Shukla VK et al. (1999) Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. British Journal of Clinical Pharmacology, 48, 168-179.
17. Cato A Jr, Qian J, Hsu A, Levy B, Leonard J, Granneman R (1998) Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy, 42, 1788-1793.
18. Nagai K, Shimizu T, Togo A et al. (1997) Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. The Journal of Antimicrobial Chemotherapy, 39, 295-296.
19. Yamagata T, Momoi MY, Murai K, Ikematsu K, Suwa K, Sakamoto K, Fujimura A (1998) Panipenembetamipron and decreases in serum valproic acid concentration. Therapeutic Drug Monitoring, 20, 396-400.
20. Coves Orts FJ, Borras Blasco J, Navarro Ruiz A, Murcia Lopez A, Palacios Ortega F (2005) Acute seizures due to a probable interaction between valproic acid and meropenem. The Annals of Pharmacotherapy, 39, 533-537.
21. Llinares Tello F, Bosacoma Ros N, Hernandez Prats C, Climent Grana E, Selva Otaolaurruchi J, Ordovas Baines JP (2003) Pharmacokinetic interaction between valproic acid and carbapenem-like antibiotics: a discussion of three cases. Farmacia hospitalaria, 27, 258-263.
22. Clause D, Decleire PY, Vanbinst R, Soyer A, Hantson P (2005) Pharmacokinetic interaction between valproic acid and meropenem. Intensive Care Medicine, 31, 1293-1294.
23. De Turck BJ, Diltoer MW, Cornelis PJ, Maes V, Spapen HD, Camu F, Huyghens LP (1998) Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. The Journal of Antimicrobial Chemotherapy, 42, 563-564.
24. Santucci M, Parmeggiani A, Riva R (2005) Seizure worsening caused by decreased serum valproate during meropenem therapy. Journal of Child Neurology, 20, 456-457.
25. Nacarkucuk E, Saglam H, Okan M (2004) Meropenem decreases serum level of valproic acid. Pediatric Neurology, 31, 232-234.
26. Sheehan NL, Brouillette MJ, Delisle MS, Allan J (2006) Possible interaction between lopinavir/ritonavir and valproic acid exacerbates bipolar disorder. The Annals of Pharmacotherapy, 40, 147-150.
27. Sidhu J, Job S, Singh S, Philipson R (2006) The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. British Journal of Clinical Pharmacology, 61, 191-199.
28. Sabers A, Buchholt JM, Uldall P, Hansen EL (2001) Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Research, 47, 151-154.
29. Ebert U, Thong NQ, Oertel R, Kirch W (2000) Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. European Journal of Clinical Pharmacology, 56, 299-304.
30. van der Lee MJ, Dawood L, Ter Hofstede HJ et al. (2006) Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clinical Pharmacology and Therapeutics, 80, 159-168.
31. Abernethy DR, Greenblatt DJ, Ameer B, Shader RI (1985) Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. The Journal of Pharmacology and Experimental Therapeutics, 234, 345-349.
32. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB (1984) Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clinical Pharmacology and Therapeutics, 36, 683-690.
33. Kroboth PD, Smith RB, Stoehr GP, Juhl RP (1985) Pharmacodynamic evaluation of the benzodiazepineoral contraceptive interaction. Clinical Pharmacology and Therapeutics, 38, 525-532.
34. Markowitz JS, Devane CL, Liston HL, Boulton DW, Risch SC (2002) The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clinical Pharmacology and Therapeutics, 71, 30-38.
35. Baber N, Halliday L, Sibeon R, Littler T, Orme ML (1978) The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study. Clinical Pharmacology and Therapeutics, 24, 298-307.
36. Kamali F (1993) The effect of probenecid on paracetamol metabolism and pharmacokinetics. European Journal of Clinical Pharmacology, 45, 551-553.
37. Baraka OZ, Truman CA, Ford JM, Roberts CJ (1990) The effect of propranolol on paracetamol metabolism in man. British Journal of Clinical Pharmacology, 29, 261-264.
38. Itoh H, Nagano T, Hayashi T, Takeyama M (2000) Ranitidine increases bioavailability of acetaminophen by inhibiting first-pass glucuronidation in man. Pharmacy and Pharmacology Communications, 6, 495-500.
39. Abernethy DR, Divoll M, Ochs HR, Ameer B, Greenblatt DJ (1982) Increased metabolic clearance of acetaminophen with oral contraceptive use. Obstetrics and Gynecology, 60, 338-341.
40. Ochs HR, Greenblatt DJ, Verburg Ochs B, Abernethy DR, Knuchel M (1984) Differential effects of isoniazid and oral contraceptive steroids on antipyrine oxidation and acetaminophen conjugation. Pharmacology, 28, 188-195.
41. Mitchell MC, Hanew T, Meredith CG, Schenker S (1983) Effects of oral contraceptive steroids on acetaminophen metabolism and elimination. Clinical Pharmacology and Therapeutics, 34, 48-53.
42. Bannier A, Comet F, Soubeyrand J, Brazier JL, Chauliac F (1985) Effect of probenecid on isofezolac kinetics. European Journal of Clinical Pharmacology, 28, 433-437.
43. Foster RT, Jamali F, Russell AS (1989) Pharmacokinetics of ketoprofen enantiomers in cholecystectomy patients: influence of probenecid. European Journal of Clinical Pharmacology, 37, 589-594.
44. Upton RA, Williams RL, Buskin JN, Jones RM (1982) Effects of probenecid on ketoprofen kinetics. Clinical Pharmacology and Therapeutics, 31, 705-712.
45. Runkel R, Mroszczak E, Chaplin M, Sevelius H, Segre E (1978) Naproxen-probenecid interaction. Clinical Pharmacology and Therapeutics, 24, 706-713.
46. Smith PC, Langendijk PN, Bosso JA, Benet LZ (1985) Effect of probenecid on the formation and elimination of acyl glucuronides: studies with zomepirac. Clinical Pharmacology and Therapeutics, 38, 121-127.
47. Macdonald JI, Wallace SM, Herman RJ, Verbeeck RK (1995) Effect of probenecid on the formation and elimination kinetics of the sulphate and glucuronide conjugates of diflunisal. European Journal of Clinical Pharmacology, 47, 519-523.
48. Dickinson RG, King AR, McKinnon GE, Hooper WD, Eadie MJ, Herkes GK (1993) Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugates of diflunisal. British Journal of Clinical Pharmacology, 35, 609-613.
49. Zucker K, Rosen A, Tsaroucha A et al. (1997) Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunology, 5, 225-232.
50. Kuypers DR, Verleden G, Naesens M, Vanrenterghem Y (2005) Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clinical Pharmacology and Therapeutics, 78, 81-88.
51. Monig H, Baese C, Heidemann HT, Ohnhaus EE, Schulte HM (1990) Effect of oral contraceptive steroids on the pharmacokinetics of phenprocoumon. British Journal of Clinical Pharmacology, 30, 115-118.
52. Veenendaal JR, Brooks PM, Meffin PJ (1981) Probenecidclofibrate interaction. Clinical Pharmacology and Therapeutics, 29, 351-358.
53. Miners JO, Robson RA, Birkett DJ (1984) Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibric acid elimination. British Journal of Clinical Pharmacology, 18, 240-243.
54. Ouellet D, Hsu A, Qian J et al. (1998) Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. British Journal of Clinical Pharmacology, 46, 111-116.
55. Wilde MI, Langtry HD (1993) Zidovudine: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs, 46, 515-578.
56. Trapnell CB, Klecker RW, Jamis Dow C, Collins JM (1998) Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrobial Agents and Chemotherapy, 42, 1592-1596.
57. Zaccara G, Messori A, Moroni F (1988) Clinical pharmacokinetics of valproic acid-1988. Clinical Pharmacokinetics, 15, 367-389.
58. Nakajima Y, Mizobuchi M, Nakamura M et al. (2004) Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metabolism and Disposition, 32, 1383-1391.
59. Kumar GN, Grabowski B, Lee R, Denissen JF (1996) Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538). Drug Metabolism and Disposition, 24, 615-617.
60. Reimers A, Helde G, Brodtkorb E (2005) Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia, 46, 1414-1417.
61. Helleberg L (1981) Clinical pharmacokinetics of indomethacin. Clinical Pharmacokinetics, 6, 245-258.
62. Kwan KC, Breault GO, Umbenhauer ER, McMahon FG, Duggan DE (1976) Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. Journal of Pharmacokinetics and Biopharmaceutics, 4, 255-280.
63. Duggan DE, Hogans AF, Kwan KC, McMahon FG (1972) The metabolism of indomethacin in man. The Journal of Pharmacology and Experimental Therapeutics, 181, 563-575.
64. Duggan DE, Hooke KF, White SD, Noll RM, Stevenson CR (1977) The effects of probenecid upon the individual components of indomethacin elimination. The Journal of Pharmacology and Experimental Therapeutics, 201, 463-470.
65. Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare (1994) A report on investigation of side effects of sorivudine: deaths caused by interactions between sorivudine and 5-FU prodrugs (confidential internal report). Tokyo: Japanese Ministry of Health and Welfare.
66. Okuda H, Ogura K, Kato A, Takubo H, Watabe T (1998) A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. The Journal of Pharmacology and Experimental Therapeutics, 287, 791-799.
67. Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare. (1997) Guideline for package inserts of prescription drugs. Notification no. 59 of the safety division (April 25). Tokyo: Japanese Ministry of Health and Welfare.
68. Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare (1997) Guideline for package inserts of prescription drugs. Notification no. 606 of Pharmaceutical Affairs Bureau (April 25). Tokyo: Japanese Ministry of Health and Welfare.
69. Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare (1997) Guideline for precautions for prescription drugs. Notification no. 607 of Pharmaceutical Affairs Bureau (April 25). Tokyo: Japanese Ministry of Health and Welfare.
70. Yoshida N, Yamada A, Mimura Y, Kawakami J, Adachi I (2006) Trends in new drug interactions for pharmaceutical products in Japan. Pharmacoepidemiology and Drug Safety, 15, 421-427.